16 Jan 2017 07:00
16 January 2017
Â
Â
Diurnal Group plc
("Diurnal" or the "Company")
Â
Directors' Dealings
Â
Â
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, received notification of the following Directors' share purchases on 13 January 2017:
Â
Peter Allen, Non-executive Chairman, purchased 40,000 ordinary shares of 5.0 pence each in the Company ("Ordinary Shares") at a price of 105 pence per Ordinary Share. Following the transaction Peter Allen has a total interest of 74,722 Ordinary Shares, representing 0.14% of the total voting rights.
Â
Sam Williams, Non-executive Director, purchased 9,248 Ordinary Shares at a price of 108 pence per Ordinary Share. Following the transaction Sam Williams has a total interest of 46,748 Ordinary Shares, representing 0.09% of the total voting rights (this includes 37,500 Ordinary Shares beneficially held via IP2IPO Nominees).
Â
John Goddard, Independent Non-executive Director, purchased 9,248 Ordinary Shares at a price of 108 pence per Ordinary Share. Following the transaction John Goddard has a total interest of 16,192 Ordinary Shares, representing 0.03% of the total voting rights.
Â
Â
Â
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, CEO | |
Richard Bungay, CFO Â | |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam | |
Corporate Broking: James Black | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell |
Â
Notes to Editors
Â
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
Â
For further information about Diurnal, please visit www.diurnal.co.ukÂ
Â
Â
DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS
Â
Â
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Peter Allen | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Non-Executive Chairman | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 5p each. Â GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s): Â |
| ||||
d) | Aggregated information:  | Aggregated volume: 40,000 Price: £42,000.00 | ||||
e) | Date of the transaction: | 13 January 2017 | ||||
f) | Place of the transaction: | XLON |
Â
5. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Sam Williams | ||||
6. | Reason for the notification | |||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial | ||||
7. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | n/a | ||||
8. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 5p each. Â GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s): Â |
| ||||
d) | Aggregated information:  | Aggregated volume: 9,248 Price: £9987.84 | ||||
e) | Date of the transaction: | 13 January 2017 | ||||
f) | Place of the transaction: | XLON |
Â
9. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | John Goddard | ||||
10. | Reason for the notification | |||||
a) | Position/status: | Non-Executive Director | ||||
b) | Initial notification/Amendment: | Initial | ||||
11. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | n/a | ||||
12. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 5p each. Â GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s): Â |
| ||||
d) | Aggregated information:  | Aggregated volume: 9,248 Price: £9987.84 | ||||
e) | Date of the transaction: | 13 January 2017 | ||||
f) | Place of the transaction: | XLON |
Â